Author(s): Ganesh G. Dhakad, Rohit V. Patil, Tejas I. Chaudhari, Paresh A. Patil.

Email(s): Email ID Not Available

DOI: 10.52711/2321-5836.2021.00030   

Address: Ganesh G. Dhakad, Rohit V. Patil, Tejas I. Chaudhari, Paresh A. Patil.
Ahinsa Institute of Pharmacy, Dondaicha 425408.
*Corresponding Author

Published In:   Volume - 13,      Issue - 4,     Year - 2021


ABSTRACT:
In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous (IV) remdesivir was performed. Remdesivir, an anti-viral prodrug originally developed to treat Ebola virus disease, has shown broad spectrum activity against the Coronavirus family. A recent case report reported improvement of clinical symptoms with remdesivir in a patient with COVID-19. After conducting a systematic search of 18 clinical trial registries and three large scientific databases, we identified 86 potentially eligible items. Following removal of duplicates (n = 21), eligible studies were reviewed independently by two authors. After the first round of screening, inter-rater agreement was 98.5% (? = 0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven ongoing and recruiting clinical trials of remdesivir (100–200 milligrams, intravenous [IV]) were included. We identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement (n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 1). Secondary outcomes in all identified studies included documentation of adverse events. Phase 3 trials are expected to be completed between April 2020–2023. Therefore, despite supportive data from in vitro and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side effects remain incompletely defined in the human population. But the remdesivir is also harmful for the people because of it can have some side effects such as mentioned in the following information. There are so many type of disease started form the treatment of COVID-19 with the Remdesivir that also mentioned in the following review paper.


Cite this article:
Ganesh G. Dhakad, Rohit V. Patil, Tejas I. Chaudhari, Paresh A. Patil. Review on Adverse effects or side effects of Remdisivir. Research Journal of Pharmacology and Pharmacodynamics. 2021;13(4):162-6. doi: 10.52711/2321-5836.2021.00030

Cite(Electronic):
Ganesh G. Dhakad, Rohit V. Patil, Tejas I. Chaudhari, Paresh A. Patil. Review on Adverse effects or side effects of Remdisivir. Research Journal of Pharmacology and Pharmacodynamics. 2021;13(4):162-6. doi: 10.52711/2321-5836.2021.00030   Available on: https://rjppd.org/AbstractView.aspx?PID=2021-13-4-9


REFERENCE:
1.    Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B,Wang Q,Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL, Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Journal of Medicinal Chemistry. 2017 Mar 9; [PubMed PMID: 28124907]
2.    Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. The Journal of Biological Chemistry. 2020 Apr 10; [PubMed PMID: 32094225]
3.    Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR, Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 Mar 6; [PubMed PMID: 29511076]
4.    Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD, Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science. 2020 May 27; [PubMed PMID: 32483554
5.    Amirian ES, Levy JK, Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health (Amsterdam, Netherlands). 2020 Jun; [PubMed PMID: 32258351]
6.    Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP, Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Reports. 2020 Jul 21; [PubMed PMID: 32668216]
7.    Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, Ling J, Vu A, German P, Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Clinical and Translational Science. 2020 Sep; [PubMed PMID: 32589775]
8.    Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, Babusis D, Porter D, Wei X, Ling J, Reddy YS, German P, Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clinical Pharmacokinetics. 2021 Mar 30 [PubMed PMID: 33782830]
9.    Yang K, What Do We Know About Remdesivir Drug Interactions? Clinical and Translational Science. 2020 Sep [PubMed PMID: 32402130]
10.    Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J,Lane HC, Muyembe-Tamfum JJ, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J, A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. The New England Journal of Medicine. 2019 Dec 12; [PubMed PMID: 31774950]
11.    Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S,Gao L,Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H,Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X,Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England). 2020 May 16; [PubMed PMID: 32423584]
12.    Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y, Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet. Infectious Diseases. 2020 Jun; [PubMed PMID: 32224310]
13.    Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nature Medicine. 2020 Jun; [PubMed PMID: 32327757]
14.    Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, Sen Gupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A, Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England Journal of Medicine. 2020 May 27; [PubMed PMID: 32459919]
15.    Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, Kojic EM, Hirshberg A, Suarez JF, Sobieszczyk ME, Marks KM, Mazur S, Big C, Manuel O, Morlin G, Rose SJ, Naqvi M, Goldfarb IT, DeZure A, Telep L, Tan SK, Zhao Y, Hahambis T, Hindman J, Chokkalingam AP, Carter C, Das M, Osinusi AO, Brainard DM, Varughese TA, Kovalenko O, Sims MD, Desai S, Swamy G, Sheffield JS, Zash R, Short WR, Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America. 2020 Oct 8; [PubMed PMID: 33031500]

Recomonded Articles:

Author(s): Rohit R. Patil, Mayur A. Chaudhari, Tushar A. Deshmukh

DOI: 10.5958/2321-5836.2018.00016.2         Access: Open Access Read More

Author(s): Gharge Deepali, Bavaskar Sunil, Todkar Pavan,Dhabale Pandurang.

DOI: Not Available         Access: Open Access Read More

Author(s): Manan A Patel, Chetan M Patel, Dipen B Patel, IS Anand , CN Patel.

DOI: Not Available         Access: Open Access Read More

Author(s): Parag Jain, Anand Surana, Ravindra Pandey, Shiv Shankar Shukla.

DOI: Not Available         Access: Open Access Read More

Author(s): Paresh A. Patil, Ritik. S. Jain

DOI: 10.5958/2321-5836.2020.00014.2         Access: Open Access Read More

Author(s): Dr. Ritika Gupta, Dr. Rashmi Saikhedkar

DOI: 10.5958/2321-5836.2019.00014.4         Access: Open Access Read More

Author(s): Ravi Kumar, Sachin Tyagi, Parveen Kumar

DOI: 10.5958/2321-5836.2020.00030.0         Access: Open Access Read More

Author(s): Rohit Kumar, Anshul Chawla, Gaganpreet, Diksha

DOI: 10.5958/2321-5836.2020.00021.X         Access: Open Access Read More

Author(s): Vandna Dewangan, Ram Sahu, Trilochan Satapathy, Amit Roy

DOI: 10.5958/2321-5836.2020.00031.2         Access: Open Access Read More

Author(s): Saxena Pranjal, Goswami Raksha, Pandey Haymanshu, Kumawat Deepak, Chandy Steffy Mary

DOI: 10.5958/2321-5836.2021.00005.7         Access: Open Access Read More

Author(s): Mahesh Babasaheb Kolap, Abhijeet Vijay Dashwant

DOI: 10.52711/2321-5836.2021.00019         Access: Closed Access Read More

Author(s): Ganesh G. Dhakad, Rohit V. Patil, Tejas I. Chaudhari, Paresh A. Patil.

DOI: 10.52711/2321-5836.2021.00030         Access: Closed Access Read More

Research Journal of Pharmacology and Pharmacodynamics (RJPPD) is an international, peer-reviewed journal....... Read more >>>

RNI: Not Available                     
DOI: 10.5958 2321-5836 


Recent Articles




Tags